Tempus, a leader in artificial intelligence and precision medicine, today announced additional funding of approximately $275 million through a combination of equity from existing investors, which Tempus sold at the same price per share as its previous fundraising round, and debt financing from funds managed by Ares Management. In total, Tempus has now raised over $1.3 billion.
The company is using the additional funds to scale its operations and capabilities, with a focus on building upon its disease agnostic platform designed to aggregate de-identified data and develop insights to power intelligent diagnostics. Tempus’ AI-enabled platform produces results that are contextualized for each specific patient and can help physicians personalize treatment decisions for their patients.
“In the last seven years, we’ve made great strides in developing and deploying smarter diagnostics not only in oncology, but neuropsychiatry, infectious disease, and cardiology,” said Eric Lefkofsky, Founder and CEO at Tempus. “We are committed to achieving our mission in applying AI to healthcare broadly with a focus on deploying solutions at scale that have real impact on patient care today and research in the future.”
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.